FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

OMB APPROVAL												
OMB Number:	3235-0287											
Estimated average burden												
hours per response:	0.5											

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Militello John					RC	2. Issuer Name and Ticker or Trading Symbol ROCKET PHARMACEUTICALS, INC. [RCKT]									ieck all appli Directi	icable) or r (give title	ng Per	son(s) to Iss 10% Ov Other (s below)	vner	
' '	(Last) (First) (Middle) C/O ROCKET PHARMACEUTICALS, INC.						3. Date of Earliest Transaction (Month/Day/Year) 11/14/2023									See R	Remai	rks		
9 CEDARBROOK DRIVE					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								Lin	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person					
(Street)	URY N	IJ	08512													filed by Mo		n One Repo		
(City) (State) (Zip)					Rule 10b5-1(c) Transaction Indication															
						Check satisfy	this bo	ox to indi firmative	icate that defense	a trans conditio	action was ons of Rule	made pu 10b5-1(c	rsuan c). See	t to a cor e Instructi	tract, instruct on 10.	ion or writter	n plan 1	that is intende	ed to	
		Tabl	le I - Nor	า-Deriv	ative	Sec	uritie	es Ac	quired	, Dis	posed (of, or	Ben	eficia	ly Owne	d				
1. Title of Security (Instr. 3) 2. Trans Date (Month//					ar) E	P.A. Deemed Execution Date, f any Month/Day/Year		Code (Instr.		4. Securities Acqui Disposed Of (D) (In 5)				Benefici	es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(A (D	A) or D)	Price	Transac (Instr. 3	tion(s)				
Common Stock ⁽¹⁾			11/14	4/2023				М		725 ⁽	1) A		\$0	9,485			D			
		Т									osed of onverti				/ Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,	4. Transaction Code (Instr 8)				6. Date E Expiratio (Month/I		7. Title and Amount of Securities Underlying Derivative Sec (Instr. 3 and 4			8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly D	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)		Date Exercisa		xpiration ate	Title	C	Amount or Number of Shares						
Restricted Stock	(2)	11/14/2023			M			725	(3)		(3)	Commo		725	\$0	3,628		D		

Explanation of Responses:

- 1. Represents shares of Common Stock received upon vesting of a restricted stock unit ("RSU") award.
- 2. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- 3. One-third (1/3) of such RSUs became fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years.

Remarks:

VP, Principal Accounting Officer and Interim Principal Financial Officer

/s/ Martin Wilson, as attorneyin-fact for John Militello

11/16/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.